Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT plus toripalimab with paclitaxel and cisplatin for recurrent or advanced esophageal squamous cell carcinoma
ChiCTR2600125208Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Jiaxing University
- Start
- May 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Affiliated Hospital of Jiaxing University. Primary endpoint: 6-month progression-free survival rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
toripalimabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600125208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125208.